ROSA-BJORKESON DAGMAR 4

4 · INTERCEPT PHARMACEUTICALS, INC. · Filed May 25, 2023

Insider Transaction Report

Form 4
Period: 2023-05-24
Transactions
  • Award

    Common Stock

    2023-05-24+8,11126,391 total
  • Award

    Option to Purchase Common Stock

    2023-05-24+12,54712,547 total
    Exercise: $9.17Exp: 2033-05-24Common Stock (12,547 underlying)
Footnotes (2)
  • [F1]Represents restricted stock units granted to the Reporting Person. Each restricted stock unit represents a contingent right to receive one share of the Issuer's Common Stock. All of the shares subject to the award shall vest on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders.
  • [F2]All of the options subject to the award shall vest and become exercisable on the earlier of (i) the one-year anniversary of the date of grant and (ii) the day immediately preceding the date of the Issuer's 2024 Annual Meeting of Stockholders.

Documents

1 file
  • 4
    tm2317083-4_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT